Products
| Product | Strength | Pack Size |
|---|---|---|
| Cisplatin Concentrate for Solution for Infusion (Cisteen) | 50mg/50ml | 1 vial / box |
| Docetaxel Concentrate for Solution for Infusion | 20mg/1ml | 1 vial / box |
| Docetaxel Concentrate for Solution for Infusion | 80mg/4ml | 1 vial / box |
| Docetaxel Concentrate for Solution for Infusion | 160mg/8ml | 1 vial / box |
| Erlotinib Tablets (Erlonat) | 25mg | 30 tablets / box |
| Erlotinib Tablets (Erlonat) | 100mg | 30 tablets / box |
| Erlotinib Tablets (Erlonat) | 150mg | 30 tablets / box |
| Gefitinib Tablets | 250mg | 30 tablets / box |
| Gemcitabine Powder for Solution for Infusion | 200mg | 1 vial / box |
| Gemcitabine Powder for Solution for Infusion | 1g | 1 vial / box |
| Pemetrexed Powder for Concentrate for Solution for Infusion | 100mg | 1 vial / box |
| Pemetrexed Powder for Concentrate for Solution for Infusion | 500mg | 1 vial / box |
* The above product list shows our products which are approved by Hong Kong Department of Health only. It does not mean that all products are already placed in the market. For any product or business enquiries please contact us at ichk@ichk.org or (852) 2891 0581 for further details.
Lung Cancer
Lung cancer is the first leading cause of cancer deaths in Hong Kong. A total of 3853 people died from this cancer in 2018. Patients are mostly presented with symptoms of cough, hemoptysis, chest pain and dyspnea. Currently, targeted therapy and chemotherapy are available for treatment of lung cancers.
Targeted therapy
EGFR-TKIs (e.g. Erlotinib, Gefitinib) are the first-line treatment option for EGFR-positive non-small cell lung cancer (NSCLC). They are not indicate for small cell lung cancer (SCLC). They inhibit the epidermal growth factor receptor to induce cancer cell death. As a targeted therapy, EGFR-TKIs are better tolerated than chemotherapy. The most common side effects are rash and diarrhea, which are manageable.
Chemotherapy
Platinum drugs (e.g. Cisplatin, Carboplatin) are the first-line treatment option for SCLC and NSCLC. However, platinum-based chemotherapy can lead to severe side effects including nephrotoxicity and emesis.
Antimetabolites (e.g. Pemetrexed, Gemcitabine) are indicated for NSCLC. They can be used as monotherapy or in combination with Cisplatin. A survival advantage is observed for Cisplatin/Pemetrexed in non-squamous histology, while a survival advantage is observed for Cisplatin/Gemcitabine in squamous histology. Taxanes (e.g. Paclitaxel, Docetaxel) are also indicated for NSCLC in combination with Cisplatin.
Targeted therapy
EGFR-TKIs (e.g. Erlotinib, Gefitinib) are the first-line treatment option for EGFR-positive non-small cell lung cancer (NSCLC). They are not indicate for small cell lung cancer (SCLC). They inhibit the epidermal growth factor receptor to induce cancer cell death. As a targeted therapy, EGFR-TKIs are better tolerated than chemotherapy. The most common side effects are rash and diarrhea, which are manageable.
Chemotherapy
Platinum drugs (e.g. Cisplatin, Carboplatin) are the first-line treatment option for SCLC and NSCLC. However, platinum-based chemotherapy can lead to severe side effects including nephrotoxicity and emesis.
Antimetabolites (e.g. Pemetrexed, Gemcitabine) are indicated for NSCLC. They can be used as monotherapy or in combination with Cisplatin. A survival advantage is observed for Cisplatin/Pemetrexed in non-squamous histology, while a survival advantage is observed for Cisplatin/Gemcitabine in squamous histology. Taxanes (e.g. Paclitaxel, Docetaxel) are also indicated for NSCLC in combination with Cisplatin.